How AI, adaptive therapy, and precision tools are transforming lung cancer radiotherapy, making treatments faster, safer and ...

Stereotactic Body Radiation Therapy (SBRT) was the ticket. I felt such confidence with my physician and his team as we tackled the two areas of inflamed lymph nodes. The unknown is so scary. So, I ...

More information: Daniel E. Oliver et al, Early-Stage Primary Lung Neuroendocrine Tumors Treated with Stereotactic Body Radiotherapy: A Multi-Institution Experience, International Journal of ...

The current reference 16, "Kwon JH, Bae SH, Kim JY, et al: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or ...

More information: Nicholas van As et al, Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2403365 ...

Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase ...

Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO ...

TOPLINE: Stereotactic body radiotherapy (SBRT) and hypofractionated conventional radiotherapy led to similar tumor control and survival outcomes at 3 years in patients with peripheral and central ...

Stereotactic body radiotherapy is an effective treatment for patients with lung neuroendocrine tumors Moffitt study shows this approach is effective for this rare tumor Peer-Reviewed Publication ...

Stereotactic body radiotherapy (SBRT) can be delivered in only 3 to 5 days, does not require concurrent chemotherapy, and has limited toxicity, and tumor control rates appear to be equivalent to or ...

Cite this: Emerging Application of Stereotactic Body Radiation Therapy for Gynecologic Malignancies - Medscape - Jul 01, 2011.

Quick Take Stereotactic Body Radiotherapy and Localized Prostate Cancer DOI: 10.1056/NEJMdo007682 Save ...